NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Hemerion Therapeutics

Hemerion Therapeutics

Private
Villeneuve-d'AscqHealthcare & Life Scienceshttps://hemerion.com/

Last Round

Series A

May 22, 2025

Est. Valuation

$32.94M

Total Funding Raised

$29.21M

Company Overview

Hemerion Therapeutics is a biotechnology company that develops therapeutic solutions combining photosensitizing molecules and laser light technologies to treat resistant tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

photodynamic therapyPDTglioblastoma treatmentphotosensitizerneuro-oncologydrug-device combinationbrain tumor therapylight delivery systembiotechmedtechcancer therapeuticsclinical-stage biotechintraoperative therapylaser medical device

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hemerion Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Hemerion Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Hemerion Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 22, 2025
Series AMar 31, 2025
Series AMar 1, 2025
GrantApr 14, 2023
SeedApr 14, 2022
Seed
Jun 1, 2021

Key People

Founding team and executive leadership

Maximilien Vermandel

Chief Executive Officer

Executive Team

Michel Andraud

Chief Financial Officer

Executive Team

Hemerion Therapeutics Investors

Notable investors and investment history

Hemerion Therapeutics investors
InvestorRounds
BpifranceSeries A, Seed
European Regional Development FundSeries A
FIRA Nord-Est 2Series A
FinorpaSeries A, Seed
Siparex GroupSeries A
Finovam GestionSeries A, Seed
BpifranceSeries A, Grant, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2025

    $7M round completed.

  • Apr 14, 2023

    $2.16M grant received from Bpifrance.

Hemerion Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hemerion Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hemerion Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersVilleneuve-d'Ascq
Employee Range17
Year Founded2020
Last FundingMay 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.